CRISPR Therapeutics AG
CRSP- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001674416
In the last 90 days, CRISPR Therapeutics AG insiders filed 0 open-market purchases and 2 sales; 525 institutions reported holding it in 13F filings for Q2 2026, worth $4.16B in total; ARK Invest is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by CRISPR Therapeutics AG insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 2 insiders, $1.41M in total
- Insiders trading
- 2
- Net value
- −$1.41M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for CRISPR Therapeutics AG, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Kasinger James R. | General Counsel and Secretary | 94,784 | Sep 24, 2026 | 8 |
| Behbahani Ali | Director | 16,637 | Sep 21, 2026 | 3 |
| Prasad Raju | Chief Financial Officer | 14,815 | Aug 11, 2026 | 8 |
| Mahatme Sandesh | Director | – | Jun 9, 2026 | 1 |
| Fardis Maria | Director | – | Jun 9, 2026 | 1 |
| George Simeon | Director | 1,730,179Indirect | Jun 9, 2026 | 1 |
| Greene John | Director | 7,000 | Jun 9, 2026 | 1 |
| High Katherine A | Director | – | Jun 9, 2026 | 1 |
| Morrison Briggs | Director | – | Jun 9, 2026 | 1 |
| Treco Douglas A | Director | 22,000 | Jun 9, 2026 | 1 |
| Fleming Harold Edward | Director | – | Jun 9, 2026 | 1 |
| Rommel Christian | Director | – | Jun 9, 2026 | 1 |
| Patel Naimish | Chief Medical Officer | 19,357 | Jun 2, 2026 | 6 |
| Kulkarni Samarth | Chief Executive Officer | 255,501 | Mar 24, 2026 | 9 |
| Bruno Julianne | Chief Operating Officer | 10,544 | Mar 24, 2025 | 0 |
| Morrow Phuong Khanh | Chief Medical Officer | 4,411 | Oct 17, 2023 | 0 |
| Smith Brendan | Chief Financial Officer | 5,072 | Feb 22, 2023 | 0 |
| Klein Lawrence Otto | CBO & COO | 26,797 | Aug 18, 2022 | 0 |
| Bolzon Bradley J PhD | Director | 148,831Indirect | Jun 10, 2022 | 0 |
| Ho Tony W | Executive VP, Head of R&D | 52,364 | Dec 7, 2021 | 0 |
| Tomsicek Michael John | Chief Financial Officer | 1,891 | Aug 10, 2021 | 0 |
| Novak Rodger | President | 573,007 | Jul 1, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 15, 2025 (view filing) | Oct 14 | 1 day | Kulkarni SamarthChief Executive Officer | SSale | −4.24K | $66.60 | −$282.5K | −2.0%205.1K after | |
| Oct 20, 2025 (view filing) | Oct 17 | 3 days | Kulkarni SamarthChief Executive Officer | SSale | −50.9K | $67.91 | −$3.46M | −16.7%254.2K after | |
| Dec 23, 2025 (view filing) | Dec 22 | 1 day | Prasad RajuChief Financial Officer | SSale | −10.0K | $55.95 | −$559.5K | −59.6%6.77K after | 3 lots10b5-1 |
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Prasad RajuChief Financial Officer | SSale | −29.7K | $60.16 | −$1.79M | −81.4%6.77K after | 3 lots10b5-1 |
| Jan 22, 2026 (view filing) | Jan 20-22 | 2 days | Kulkarni SamarthChief Executive Officer | SSale | −90.0K | $57.40 | −$5.17M | −40.1%134.2K after | 3 lots10b5-1 |
| Jan 26, 2026 (view filing) | Jan 22 | 4 days | Prasad RajuChief Financial Officer | SSale | −35.0K | $60.19 | −$2.10M | −83.8%6.77K after | 10b5-1 |
| Jan 27, 2026 (view filing) | Apr 3, 2025 | 299 daysLate | Patel NaimishChief Medical Officer | PPurchase | +1.51K | $32.96 | +$49.7K | New position1.51K after | |
| Feb 20, 2026 (view filing) | Feb 19 | 1 day | Kasinger James R.General Counsel and Secretary | SSale | −2.11K | $52.58 | −$111.0K | −2.4%85.1K after | |
| Feb 20, 2026 (view filing) | Feb 19 | 1 day | Kulkarni SamarthChief Executive Officer | SSale | −6.97K | $52.58 | −$366.3K | −3.0%226.1K after | |
| Mar 12, 2026 (view filing) | Mar 11 | 1 day | Kulkarni SamarthChief Executive Officer | SSale | −9.80K | $52.80 | −$517.3K | −4.0%235.6K after | |
| Mar 12, 2026 (view filing) | Mar 11 | 1 day | Kasinger James R.General Counsel and Secretary | SSale | −2.80K | $52.80 | −$147.8K | −3.1%87.8K after | |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Kulkarni SamarthChief Executive Officer | SSale | −10.3K | $48.26 | −$499.4K | −4.0%245.8K after | |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Kasinger James R.General Counsel and Secretary | SSale | −3.45K | $48.26 | −$166.5K | −3.6%91.2K after | |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Prasad RajuChief Financial Officer | SSale | −9.87K | $48.26 | −$476.3K | −41.7%13.8K after | 2 lots |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Patel NaimishChief Medical Officer | SSale | −3.15K | $48.26 | −$152.0K | −19.3%13.1K after | |
| Mar 24, 2026 (view filing) | Mar 23 | 1 day | Prasad RajuChief Financial Officer | SSale | −3.71K | $46.78 | −$173.5K | −19.2%15.6K after | |
| Mar 24, 2026 (view filing) | Mar 23 | 1 day | Kulkarni SamarthChief Executive Officer | SSale | −10.0K | $46.78 | −$468.7K | −3.8%255.5K after | |
| Mar 24, 2026 (view filing) | Mar 23 | 1 day | Kasinger James R.General Counsel and Secretary | SSale | −3.18K | $46.78 | −$148.9K | −3.3%94.3K after | |
| Jun 1, 2026 (view filing) | May 29 | 3 days | Patel NaimishChief Medical Officer | SSale | −3.79K | $55.62 | −$210.6K | −16.4%19.4K after | |
| Sep 21, 2026 (view filing)6:40 PM ET | Sep 17 | 4 days | Behbahani AliDirector | SSale | −13.7K | $57.09 | −$780.9K | −45.1%16.6K after | |
| Sep 24, 2026 (view filing)5:35 PM ET | Sep 22 | 2 days | Kasinger James R.General Counsel and Secretary | SSale | −10.4K | $60.24 | −$626.5K | −9.9%94.8K after | 10b5-1 |